Sunitinib in combination with docetaxel and prednisone in patients with metastatic hormone-refractory prostate cancer (mHRPC) - preliminary results

Daniel J. George,Glenn Liu,George Wilding,Thomas E. Hutson,I. Chen,E. Chow Maneval,Christopher J. Logothetis,Amado J. Zurita

Sunitinib in combination with docetaxel and prednisone in patients with metastatic hormone-refractory prostate cancer (mHRPC) - preliminary results

2008

Daniel J. George
Glenn Liu
George Wilding
Thomas E. Hutson
I. Chen
E. Chow Maneval
Christopher J. Logothetis
Amado J. Zurita

5131 Background: Sunitinib malate is an oral, multitargeted tyrosine kinase inhibitor of VEGFRs, PDGFRs, KIT, FLT3, CSF-1R and RET. VEGF and PDGF overexpression have been implicated in disease prog...

Keywords:

Sunitinib
Hormone refractory prostate cancer
Oncology
Prednisone
Medicine
Internal medicine
Docetaxel
in patient
Sunitinib malate
Tyrosine-kinase inhibitor
Platelet-derived growth factor receptor

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations